October 14, 2022

Corbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

NORWOOD, Mass., Oct. 14, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announced a poster presentation at the SITC 2022 Annual Meeting being held November 8-12, 2022. The poster will share the updated preclinical validation of the drug candidate CRB-601.

**Poster Details:**

**Title:** CRB-601, a selective integrin αvβ8 blocking antibody, exhibits potent anti-tumor activity in anti-PD-1 resistant models

**Authors:** Daqing Wang, Vaishali Shinde, Maneesh Singh, Rachael Brake, and Andrew Kolodziej

**Abstract Number:** 815

**Date / Time:** November 10 – November 11, 9:00 am - 9:00 pm ET

CRB-601 is a potent and selective integrin αvβ8 blocking monoclonal antibody that can overcome tumor immune exclusion and enhance the activity of immune checkpoint inhibitors *in vivo*. Investigational New Drug (IND) enabling studies are currently underway with a plan to explore the anti-tumor activity of this agent clinically in 2023.

The CRB-601 abstract will be available on the SITC website as of November 7th and the poster will be made available on the Company website on November 10th.

**About Corbus**

Corbus is an immunology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ current pipeline includes anti-integrin monoclonal antibodies that block activation of TGFβ and small molecules that activate or inhibit the endocannabinoid system. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit [corbuspharma.com](http://corbuspharma.com). Connect with us on [Twitter](http://Twitter), [LinkedIn](http://LinkedIn) and [Facebook](http://Facebook).
Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

INVESTOR CONTACT:

Sean Moran
smoran@corbuspharma.com


SOURCE Corbus Pharmaceuticals